Dynavax Technologies Stock Price, News & Analysis (NASDAQ:DVAX)

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies Co. (NASDAQ:DVAX) released its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.63) by $0.03. The biopharmaceutical company earned $8.30 million during the quarter, compared to the consensus estimate of $8.24 million. Dynavax Technologies had a negative return on equity of 304.71% and a negative net margin of 781.10%. The firm's quarterly revenue was up 564.0% on a year-over-year basis. During the same period last year, the business posted ($0.63) earnings per share. View Dynavax Technologies' Earnings History.

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Dynavax Technologies.

4 brokerages have issued 1 year price objectives for Dynavax Technologies' shares. Their forecasts range from $13.00 to $30.00. On average, they anticipate Dynavax Technologies' stock price to reach $21.00 in the next year. This suggests a possible upside of 398.8% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

Media coverage about DVAX stock has trended neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Dynavax Technologies earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Dynavax Technologies.

Some companies that are related to Dynavax Technologies include Esperion Therapeutics (ESPR), ArQule (ARQL), Theravance Biopharma (TBPH), Dicerna Pharmaceuticals (DRNA), Gossamer Bio (GOSS), Amphastar Pharmaceuticals (AMPH), AnaptysBio (ANAB), TherapeuticsMD (TXMD), Epizyme (EPZM), Odonate Therapeutics (ODT), Y-mAbs Therapeutics (YMAB), ANI Pharmaceuticals (ANIP), Phibro Animal Health (PAHC), Athenex (ATNX) and Spectrum Pharmaceuticals (SPPI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), United Continental (UAL), Kite Pharma (KITE), Cara Therapeutics (CARA) and Micron Technology (MU).

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DVAX stock can currently be purchased for approximately $4.21.

Dynavax Technologies has a market capitalization of $274.30 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.View Additional Information About Dynavax Technologies.

The official website for Dynavax Technologies is http://www.dynavax.com/.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]